O6-benzylguanine-mediated enhancement of chemotherapy

Henry S. Friedman, Stephen Keir, Anthony E. Pegg, Peter J. Houghton, O. Michael Colvin, Robert C. Moschel, Darell D. Bigner, M. Eileen Dolan

Resultado de la investigación: Articlerevisión exhaustiva

87 Citas (Scopus)


We have previously demonstrated (A. E. Pegg, Cancer Res., 50: 6119-6129, 1990) that O6-benzylguanine (O6-BG) enhances nitrosourea, temozolomide, and cyclophosphamide activity in malignant glioma xenografts growing in athymic nude mice. More recently, we have demonstrated (V. J. Patel et al., Clin. Cancer Res., 6: 4154-4157, 2000; P. Pourquier et al., Cancer Res., 61: 53-58, 2001) that the combination of temozolomide plus irinotecan (CPT-11) displays a schedule-dependent enhancement of antitumor activity secondary to trapping of topoisomerase I by O6-methylguanine residues in DNA. These studies suggested that there might be favorable therapeutic interactions between O6-BG and combinations of 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU) plus cyclophosphamide or temozolomide plus CPT-11, respectively. Our present results indicate that the combination of cyclophosphamide plus BCNU plus O6-BG produces growth delays modestly-to-markedly-superior to combinations of cyclophosphamide with BCNU. Although the combination of temozolomide and CPT-11 reveals a marked increase in activity compared with either agent used alone, the addition of O 6-BG to this combination dramatically increased the growth delay of the O6-alkylguanine-DNA alkyltransferase (AGT)-positive malignant glioma D-456 MG. These results suggest that a Phase I trial of CPT-11 plus temozolomide plus O6-BG in AGT-positive tumors may be an important intervention to maximize the therapeutic benefits of the combination of CPT-11 and temozolomide.

Idioma originalEnglish (US)
Páginas (desde-hasta)943-948
Número de páginas6
PublicaciónMolecular cancer therapeutics
EstadoPublished - sept 2002
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'O6-benzylguanine-mediated enhancement of chemotherapy'. En conjunto forman una huella única.

Citar esto